Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -43.50% is 15% above its 5-year average of -50.95%, near the high end of its 5-year range (-142.82%–-25.26%).
As of the fiscal period ended Tuesday, June 30, 2026. 20.43% above its 12-month average of -54.67%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -43.50%.
RETURN ON INVESTED CAPITAL (ROIC)
-43.50%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-54.67%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-56.37%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-50.95%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-50.60%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
-65.50%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+20.43%
CURRENT VS 3Y AVG
+22.84%
CURRENT VS 5Y AVG
+14.62%
CURRENT VS 10Y AVG
+14.03%
CURRENT VS 15Y AVG
+33.59%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
-22.03%
vs the sector median at left
Xenetic Biosciences, Inc.
Market Cap
$4.86M
Return on Invested Capital (ROIC)
-43.50%
TTM Avg
-54.67%
3Y Avg
-56.37%
5Y Avg
-50.95%
Market Cap
$4.97M
Return on Invested Capital (ROIC)
-225.12%
TTM Avg
-13.17%
3Y Avg
-9.09%
5Y Avg
-9.09%
Market Cap
$4.72M
Return on Invested Capital (ROIC)
-38.23%
TTM Avg
-122.97%
3Y Avg
-1403.32%
5Y Avg
-860.06%
Market Cap
$4.71M
Return on Invested Capital (ROIC)
-126.69%
TTM Avg
-289.57%
3Y Avg
-198.60%
5Y Avg
-147.26%
Market Cap
$4.69M
Return on Invested Capital (ROIC)
-122.56%
TTM Avg
-179.66%
3Y Avg
-275.36%
5Y Avg
-182.57%
Market Cap
$5.12M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-67.32%
3Y Avg
-73.33%
5Y Avg
-73.33%
Market Cap
$4.55M
Return on Invested Capital (ROIC)
-246.61%
TTM Avg
-463.24%
3Y Avg
-303.42%
5Y Avg
-359.05%
Market Cap
$4.53M
Return on Invested Capital (ROIC)
-19.51%
TTM Avg
-11.65%
3Y Avg
-12.10%
5Y Avg
-17.92%
Market Cap
$5.21M
Return on Invested Capital (ROIC)
-156.69%
TTM Avg
-654.50%
3Y Avg
-599.09%
5Y Avg
-420.09%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | $4.86M | -43.50% | -54.67% | -56.37% | -50.95% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $4.97M | -225.12% | -13.17% | -9.09% | -9.09% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.72M | -38.23% | -122.97% | -1403.32% | -860.06% |
| Imunon, Inc. (IMNN)vs › | $4.71M | -126.69% | -289.57% | -198.60% | -147.26% |
| CalciMedica, Inc. (CALC)vs › | $4.69M | -122.56% | -179.66% | -275.36% | -182.57% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.12M | N/A | -67.32% | -73.33% | -73.33% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | -246.61% | -463.24% | -303.42% | -359.05% |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.53M | -19.51% | -11.65% | -12.10% | -17.92% |
| Alzamend Neuro Inc (ALZN)vs › | $5.21M | -156.69% | -654.50% | -599.09% | -420.09% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.21M | -35.07% | -9.54% | 2.54% | 2.54% |
ROIC
-43.5%
ROE
-40.8%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -43.50% |
| 2026-03-31 | -34.45% |
| 2025-12-31 | -38.33% |
| 2025-09-30 | -83.68% |
| 2025-06-30 | -73.38% |
| 2025-03-31 | -75.70% |
| 2024-12-31 | -69.99% |
| 2024-09-30 | -61.98% |
| 2024-06-30 | -67.26% |
| 2024-03-31 | -56.11% |
| 2023-12-31 | -46.10% |
| 2023-09-30 | -44.28% |
| 2023-06-30 | -38.09% |
| 2023-03-31 | -46.76% |
| 2022-12-31 | -49.23% |
| 2022-09-30 | -48.40% |
| 2022-06-30 | -49.75% |
| 2022-03-31 | -35.45% |
| 2021-12-31 | -31.24% |
| 2021-09-30 | -25.26% |
| 2021-06-30 | -142.82% |
| 2021-03-31 | -128.39% |
| 2020-12-31 | -113.85% |
| 2020-09-30 | -176.44% |
| 2020-06-30 | -67.82% |
| 2020-03-31 | -66.90% |
| 2019-12-31 | -63.95% |
| 2019-09-30 | -62.76% |
| 2019-06-30 | -46.26% |
| 2019-03-31 | -46.89% |
| 2018-12-31 | -56.71% |
| 2018-09-30 | -8.48% |
| 2018-06-30 | -10.39% |
| 2018-03-31 | -16.08% |
| 2017-12-31 | -20.72% |
| 2017-09-30 | -64.62% |
| 2017-06-30 | -55.93% |
| 2017-03-31 | -287.66% |
| 2016-12-31 | -248.23% |
| 2016-09-30 | -553.14% |
| 2016-06-30 | -542.51% |
| 2016-03-31 | -118.75% |
| 2015-12-31 | -72.15% |
| 2015-09-30 | -132.88% |
| 2015-06-30 | -104.51% |
| 2015-03-31 | -102.97% |
| 2014-12-31 | -92.48% |
| 2014-09-30 | -49.91% |
| 2013-08-31 | -213.31% |
| 2013-05-31 | -40.74% |
| 2013-02-28 | -57.10% |
| 2012-11-30 | -107.30% |
| 2012-08-31 | -97.29% |
